

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): An agent for the prevention or treatment of a disease associated with hyperglycemia, comprising as an active ingredient a selective SGLT1 inhibitor.
2. (original): An agent for the prevention or treatment as claimed in claim 1, wherein the active ingredient is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.
3. (currently amended): An agent for the prevention or treatment as claimed in claim 1 or 2, wherein the dosage form is an oral agent.
4. (currently amended): An agent for the prevention or treatment as claimed in ~~any one of claims 1-3~~claim 1, wherein the disease associated with hyperglycemia is diabetes.
5. (original): An agent for the prevention or treatment as claimed in claim 4, wherein the diabetes is postprandial hyperglycemia.
6. (currently amended): An agent for the prevention or treatment as claimed in ~~any one of claims 1 to 3~~in claim 1, wherein the disease associated with hyperglycemia is impaired glucose tolerance.
7. (currently amended): An agent for the prevention or treatment as claimed in ~~any one of claims 1 to 3~~claim 1, wherein the disease associated with hyperglycemia is diabetic complications.

PRELIMINARY AMENDMENT

8. (currently amended): An agent for the prevention or treatment as claimed in ~~any one of claims 1 to 3~~claim 1, wherein the disease associated with hyperglycemia is obesity.

9. (original): A method for the prevention or treatment of a disease associated with hyperglycemia, which comprises administering an effective amount of a selective SGLT1 inhibitor.

10. (original): A method for the prevention or treatment as claimed in claim 9, wherein the selective SGLT1 inhibitor is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.

11. (currently amended): A method for the prevention or treatment as claimed in claim 9 or 10, wherein the dosage form is an oral agent.

12. (currently amended): A method for the prevention or treatment as claimed in ~~any one of claims 9 to 11~~claim 9, wherein the disease associated with hyperglycemia is diabetes.

13. (original): A method for the prevention or treatment as claimed in claim 12, wherein the diabetes is postprandial hyperglycemia.

14. (currently amended): A method for the prevention or treatment as claimed in ~~any one of claims 9 to 11~~in claim 9, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

15. (currently amended): A method for the prevention or treatment as claimed in ~~any one of claims 9 to 11~~claim 9, wherein the disease associated with hyperglycemia is diabetic complications.

16. (currently amended): A method for the prevention or treatment as claimed in ~~any one of claims 9 to 11~~claim 9, wherein the disease associated with hyperglycemia is obesity;

PRELIMINARY AMENDMENT

17. (currently amended): ~~A use of a selective SGLT1 inhibitor~~ A method for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with hyperglycemia; which method comprises blending the selective SGLT1 inhibitor of claim 1 with a pharmaceutically acceptable additive.

18. (currently amended): ~~A use~~ method as claimed in claim 17, wherein the selective SGLT1 inhibitor is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.

19. (currently amended): ~~A use~~ method as claimed in claim 17-~~or~~~~18~~, wherein the composition is an oral agent.

20. (currently amended): ~~A use~~ method as claimed in ~~any one of claims 17 to 19~~ claim 17, wherein the disease associated with hyperglycemia is diabetes.

21. (currently amended): ~~A use~~ method as claimed in claim 20, wherein the diabetes is postprandial hyperglycemia.

22. (currently amended): ~~A use~~ method as claimed in ~~any one of claims 17 to 19~~ claim 17, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

23. (currently amended): ~~A use~~ method as claimed in ~~any one of claims 17 to 19~~ claim 17, wherein the disease associated with hyperglycemia is diabetic complications.

24. (currently amended): ~~A use~~ method as claimed in ~~any one of claims 17 to 19~~ claim 17, wherein the disease associated with hyperglycemia is obesity.

25. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the dosage form is an oral agent.

PRELIMINARY AMENDMENT

26. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is diabetes.

27. (new): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is diabetes.

28. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

29. (new): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

30. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is diabetic complications.

31. (new): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is diabetic complications.

32. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is obesity.

33. (new): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is obesity.

34. (new): A method for the prevention or treatment as claimed in claim 10, wherein the dosage form is an oral agent.

35. (new): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is diabetes.

36. (new): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is diabetes.

PRELIMINARY AMENDMENT

37. (new): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is impaired glucose tolerance.
38. (new): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is impaired glucose tolerance.
39. (new): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is diabetic complications.
40. (new): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is diabetic complications.
41. (new): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is obesity.
42. (new): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is obesity;
43. (new): A method as claimed in claim 18, wherein the composition is an oral agent.
44. (new): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is diabetes.
45. (new): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is diabetes.
46. (new): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

PRELIMINARY AMENDMENT

47. (new): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

48. (new): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is diabetic complications.

49. (new): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is diabetic complications.

50. (new): A use as claimed in claim 18, wherein the disease associated with hyperglycemia is obesity.

51. (new): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is obesity.